Wonil Kim
Chief Scientific Officer Aston Science Inc
Seminars
Thursday 10th September 2026
Moving Beyond Small Molecules: Targeting KRAS-Driven Cancers Through mRNA Vaccination & Adaptive Immune Activation
11:00 am
- Developing AST-1138, an mRNA-based therapeutic cancer vaccine engineered to address KRAS-driven malignancies through precision immune activation, offering a fundamentally distinct and complementary approach to conventional small-molecule inhibitors and targeted protein degraders
- Expanding the breadth of anti-tumor immune recognition by co-targeting both oncogenic mutant KRAS neoepitopes and immunogenic wild-type KRAS domain epitopes, harnessing a proprietary “helper-killer axis” strategy that coordinates MHC Class II–mediated CD4⁺ T helper priming with robust cytotoxic CD8⁺ T cell responses
- Advancing a next-generation immunotherapeutic paradigm powered by the Th-Vac® platform and ASEP AI epitope prediction system, enabling rational, multi-epitope vaccine design that moves beyond the resistance limitations of targeted therapies to establish durable, adaptive anti-KRAS immunity
